Pfizer-BioNTech COVID-19 Vaccine Less Effective Against Omicron: Companies

Pfizer-BioNTech COVID-19 Vaccine Less Effective Against Omicron: Companies
A vial of the Pfizer-BioNTech COVID-19 vaccine is seen in a file photograph. Justin Sullivan/Getty Images
Zachary Stieber
By Zachary Stieber, Senior Reporter
Updated:
The Pfizer-BioNTech COVID-19 vaccine is less effective against the Omicron virus variant than other strains of the CCP virus, the companies said Wednesday, citing interim results from a study they’re running.

Scientists found on average a more than 25-fold reduction in neutralizing antibodies against the Omicron variant compared to the wild type, “indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant,” the companies said in a statement.

Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth
Related Topics